Search PubMed⌕ Search

Biomedical subjects

E Czestochowska

Publications and source records attributed to E Czestochowska.

At least 19 recordsLinked to original sources
PubMed2005

Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression.

PURPOSE: The aim of this study was to assess the prognostic relevance of apoptotic index (AI), considered alone or together with expression of several proteins controlling G1 check point (p53, mdm2, pRb and p21WAF1/CIP1) in non-small cell lung cancer (NSCLC) patients. METHODS: Study group included 50 NSCLC patients who underwent curative pulmonary resection. Apoptosis was detected with the use of TUNEL technique and AI was defined as the number of apoptotic cells per 1,000 tumor cells. The expression of p53, mdm2, pRb and p21WAF1/CIP1 was assessed immunohistochemically. RESULTS: The mean and median AI calculated for all 50 patients was 14 and 9, respectively. Patients with lower (<14) and higher (> or =14) AI constituted 35 (70%) and 15 (30%) of cases, respectively. AI was not correlated with patient clinical characteristics, and expression of p53, pRb and p21WAF1/CIP1 . However, lower AI was correlated with over-expression of mdm2 protein (P=0.04). Median survival for patients with lower and higher AI was 43 months and 22 months, respectively, and 5-year survival probability-60 and 25%, respectively (P=0.03). In multivariate analysis, the only variable associated with shortened survival was AI (P=0.03, HR=2.9, 95% CI 1.95-3.86). CONCLUSIONS: These results suggest that AI correlates with mdm2 protein expression and influences survival in NSCLC.

Aged↗
PubMed1999

Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.

The aim of this study was to determine the efficacy and safety of subcutaneous weight-adjusted dose low molecular weight heparin (LMWH) compared with oral anticoagulant (OA) in the prevention of recurrent venous thromboembolism. In a prospective multicenter trial, 202 patients with symptomatic proximal deep vein thrombosis (DVT) were included. As soon as the diagnosis of DVT was confirmed by phlebography, 101 were randomly assigned to receive LMWH (nadroparin) for secondary prophylaxis and 101 to receive OA (acenocoumarol). Patients in both groups were initially treated with nadroparin in a dose of 85 anti-Xa IU/kg s.c. every 12 h. Secondary prophylaxis with either nadroparin, 85 anti-Xa IU/kg s. c. once daily, or acenocoumarol was continued for at least 3 months. Three patients in the LMWH group and 6 in the OA group were excluded from analysis for various reasons. During the one-year combined secondary prophylaxis and surveillance period, 7 of of the 98 evaluable patients (7.1%) in the LMWH group and 9 of the 95 evaluable patients (9.5%) in the OA group had a documented recurrence of venous thromboembolism (Fisher's exact test, p = 0.61). Of these, 2 patients who received LMWH and 7 patients on acenocoumarol had recurrences in the 3-month period of secondary prophylaxis. Four patients (4.1%) in the LMWH group developed bleeding complications during this study period, as compared with 7 (7.4%) in the OA group (Fisher's exact test, p = 0.37). There were two major bleedings, one in the LMWH group and one in the OA group. Eleven patients died, 5 (5.1%) in the LMWH group and 6 (6.3%) in the OA group. It is concluded that nadroparin in a dose of 85 anti-Xa IU/kg s.c. once daily provides an effective and safe alternative to oral anticoagulants in the secondary prophylaxis of DVT.

Acenocoumarol↗
PubMed1997

[Hormonal replacement therapy and body weight in postmenopausal women].

Prospective studies that included 116 postmenopausal women on hormonal replacement therapy (transdermal estradiol and medroxyprogesterone acetate orally) was performed. Body mass index (BMI), total cholesterol concentration, levels of HDL and LDL-cholesterol were measured before and after 6 and 12 months of continuous treatment. Body mass index revealed no changes during one year of therapy. HDL-cholesterol significantly increased (p < 0.05) and LDL-cholesterol was significantly decreased after 6 and 12 months of HRT.

Body Mass Index↗
PubMed1997

[Long-term prophylaxis of thromboembolism and fraxiparin].

23 consecutive patients were enrolled in the study, 21 after deep venous thrombosis, in 40% complicated by pulmonary embolism, and 2 with mechanical prosthetic heart valves with contraindications to oral anticoagulation. All of them received fraxiparine s.c. in doses of 7500 U anti-Xa daily, from at least 9 to 24 months. Fraxiparine was well tolerated. Re-thrombosis or signs of pulmonary embolisation as well as bleeding complications have not been observed. Long-term subcutaneous administration of fraxiparine is an effective and safe alternative for the prophylaxis of thromboembolism in cases with contraindication to oral anticoagulation, although the danger of osteoporosis should be considered.

Anticoagulants↗
PubMed1997

Effect of saturated air and nitrox diving on selected parameters of haemostasis.

The objective of the study was to evaluate decompression stress after air and nitrox saturated divings on the basis of the parameters of haemostasis. Before and after each diving the following examinations were performed: blood platelet count, aggregation, fibrinogen level and coagulation factors VII, X and XII. After the air saturated dives a slight reduction of factor X and XII and of fibrinogen was observed. Evaluation of haemostatis may be one of the basic elements in the assessment of decompression sickness risk.

Adult↗
PubMed1996

Influence of hormone replacement therapy (17 beta-OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1+2 and thrombin-antithrombin III complex in postmenopausal woman.

The influence of hormone replacement therapy (HRT) on coagulation system has not been completely explained yet. We measured plasma levels of prothrombin fragment F1+2 and thrombin-antithrombin III complex before the treatment and after 6 and 12 months of HRT in 116 postmenopausal women HRT considered of transdermal estradiol and oral medroxyprogesterone acetate. We observed no statistically significant differences in plasma levels of the above coagulation markers before and during the treatment.

Adult↗
PubMed1996

[Activity of endogenous anticoagulants (antithrombin III, protein C and protein S) in women after menopause treated with hormone replacement therapy (transdermal 17 beta-OH estradiol and oral medroxyprogesterone acetate)].

The influence of hormone replacement therapy (HRT) on coagulation system has not been completely explained yet. We measured plasma activities of antithrombin III, protein C and protein S before and after 6 and 12 months of HRT in 48 postmenopausal women. HRT consisted of transdermal estradiol and orally medroxyprogesterone acetate. We observed no statistically significant differences in plasma levels of the above endogenous anticoagulants before and during treatment.

Aged↗
PubMed1996

[Thromboembolism prophylaxis in pregnancy and labor].

Oral anticoagulants are contraindicated during pregnancy, especially during the I and III trimester, therefore heparin is recommended instead. We used fraxiparine s.c. once daily in prophylactic doses in 6 patients during pregnancy and labor (mean time of prophylaxis 6.5 months). Two of them received fraxiparine because of mechanical valve prosthesis, four after deep venous thrombosis occurring during the first few weeks of pregnancy. The pregnancies were uneventful, thromboembolic or haemorrhagic complications during delivery did not occur. Newborns were healthy, disturbances of hemostasis were not observed.

Anticoagulants↗
PubMed1995

[Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy].

Prospective studies that included 48 postmenopausal women on hormonal replacement therapy (transdermal estradiol and medroxyprogesterone acetate orally) was performed. Plasma activity of plasminogen activator inhibitor (PAI-1), levels of fibrinogen and serum lipids profile was measured before, after 6 and 12 months of continuous treatment. Plasma activity of PAI-1 showed significant decrease after 6 month of therapy. Plasma fibrinogen concentration significantly decreased (p < 0.05) after 12 months of treatment (271.27 +/- 71.08 vs. 238.33 +/- 34.48 mg/dl).

Adult↗
PubMed1993

Platelet function and survival in multiple myeloma.

Symptoms of haemorrhagic diathesis are frequently observed in multiple myeloma patients. Their nature is complex and is thought to be connected with platelet function disturbances, coagulation abnormalities and vascular endothelium damage. We demonstrated the shortening of platelet halflife in six myeloma patients. Disturbed thrombocytopoiesis, decreased platelet adhesion and aggregation were shown in all patients studied. The shortened platelet survival in our patients may have resulted from disturbed platelet function resulting from high immunoglobulin concentration and changes in thrombocytopoiesis.

Aged↗
PubMed1992

Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.

In a prospective multicenter trial, 149 consecutive patients with phlebographically proven proximal and/or distal deep vein thrombosis of the leg were randomly allocated to receive subcutaneously for 10 days either low molecular weight heparin CY 216 (Fraxiparine) in a fixed dose or unfractionated heparin (UFH) in doses adjusted according to the activated partial thromboplastin time. Pre- and post-treatment phlebograms were assessed blindly using the Arnesen's score system in 134 patients available for analysis of the treatment efficacy. The mean phlebographic score after 10 days of treatment was significantly decreased in both groups (p less than 0.001) in comparison with the baseline score but the difference in score changes between the two groups was not statistically significant. There was an improvement in 45/68 patients (66%) in the Fraxiparine group and in 32/66 patients (48%) in the UFH group, and an increase in the thrombus size in 10/68 (15%) and 12/66 (18%), respectively. One symptomatic non-fatal pulmonary embolism and one major bleeding episode were observed in the UFH group. During a follow-up period of 3 months, two rethromboses had occurred in the UFH group and none in the Fraxiparine group. It is concluded that subcutaneous fixed dose Fraxiparine is safe and at least as effective as subcutaneous adjusted UFH in the treatment of deep vein thrombosis.

Adult↗
PubMed1990

Effect of nitrox saturation diving upon platelet hemostasis.

Two nitrox saturation exposures (seven- and nine-days) at a pressure equivalent to 40 and 45 m (pO2 40-50 kPa) with three divers were carried out. During one exposure 6 excursions from the plateau to the depth of 70 m (one hour) and 60 m (four hours) were made. Before and after the exposures blood platelet count, aggregation and adhesion of blood cells were determined. After the first series of diving a slight increase of adhesion and aggregation was observed, after the other one, despite the larger depth and the excursions from the saturation plateau to 60 and 70 m, a slight decrease of adhesion occurred. This allows to conclude that the phenomenon is related to the decompression load degree as well as to the condition of the divers. Finding about the effect of decompression upon the processes of hemostasis may be useful for the evaluation of the verified system of saturation decompression.

Decompression↗